26 studies found for:    "Merkel cell carcinoma"
Show Display Options
Rank Status Study
1 Recruiting Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
Conditions: Merkel Cell Carcinoma;   Skin Cancer
Intervention: Drug: Cabozantinib
2 Recruiting A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma
Intervention: Biological: GLA-SE
3 Recruiting F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma
Interventions: Drug: Arm A: F16IL2 in combination with paclitaxel;   Drug: Arm B: Paclitaxel
4 Recruiting Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With 3 mg/kg BW Ipilimumab (Yervoy®) Versus Observation
Condition: Merkel Cell Carcinoma
Intervention: Drug: Ipilimumab
5 Recruiting Dose Escalation Study to Investigate Safety, PK and Anti-tumor Activity of Pasireotide in Patients With Metastatic Melanoma or Merkel Cell Carcinoma
Condition: Metastatic Melanoma and Merkel Cell Carcinoma
Intervention: Drug: Pasireotide sub-cutaneous formulation
6 Withdrawn Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma
Intervention: Drug: Ipilimumab
7 Recruiting MSB0010718C in Subjects With Merkel Cell Carcinoma
Condition: Carcinoma, Merkel Cell
Intervention: Drug: MSB0010718C
8 Recruiting Merkel Positron Emission Tomography (PET) Protocol
Condition: Merkel Cell Carcinoma
Interventions: Drug: Carboplatin;   Drug: Etoposide;   Radiation: Radiotherapy
9 Withdrawn Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy
Conditions: Merkel Cell Carcinoma;   Islet Cell Carcinoma;   Neuroendocrine Carcinoma;   Pituitary Tumor
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1;   Procedure: alternative product therapy;   Procedure: biological therapy;   Procedure: biologically based therapies;   Procedure: cancer prevention intervention;   Procedure: complementary and alternative therapy;   Procedure: differentiation therapy
10 Active, not recruiting BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors
Conditions: Ovarian Cancer;   Merkel Cell Carcinoma;   SCLC
Intervention: Drug: BB-10901
11 Suspended Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer
Conditions: Melanoma;   Merkel Cell Carcinoma;   Squamous Cell Carcinoma;   Penile Carcinoma;   Urethral Carcinoma;   Extramammary Paget's Disease;   Scrotal Carcinoma;   Anal Cancer;   Vulvar Cancer;   Skin Cancer;   Lymphadenopathy
Interventions: Procedure: Videoscopic procedure;   Procedure: Open, traditional approach
12 Completed
Has Results
The Impact of Total Body Skin Examination on Skin Cancer Detection
Conditions: Melanoma;   Basal Cell Carcinoma;   Squamous Cell Carcinoma;   Merkel Cell Carcinoma;   Skin Cancer
Intervention: Other: Inspection of covered areas
13 Completed Optical Biopsy of Human Skin in Conjunction With Laser Treatment
Conditions: Malignant Melanoma,;   Merkel Cell Carcinoma,;   Basal Cell Carcinoma,;   Squamous Cell Carcinoma;   Atypical Nevi,;   Congenital Nevi;   Seborrheic Keratosis,;   Paget's Disease;   Dermatofibroma,;   Kaposi's Sarcoma;   Hypervascular Congenital Malformations;   Port Wine Stain;   Hemangioma;   Tattoos;   Scleroderma;   Burns;   Normal Skin
Intervention: Device: OLCR,NIR/PMS,MI
14 Completed Oblimersen in Treating Patients With Merkel Cell Carcinoma
Conditions: Recurrent Neuroendocrine Carcinoma of the Skin;   Stage I Neuroendocrine Carcinoma of the Skin;   Stage II Neuroendocrine Carcinoma of the Skin;   Stage III Neuroendocrine Carcinoma of the Skin;   Stage IV Neuroendocrine Carcinoma of the Skin
Interventions: Biological: oblimersen sodium;   Other: pharmacological study;   Other: laboratory biomarker analysis
15 Recruiting Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma
Conditions: Recurrent Neuroendocrine Carcinoma of the Skin;   Stage IV Neuroendocrine Carcinoma of the Skin
Interventions: Radiation: radiation therapy;   Biological: recombinant interferon beta;   Biological: MCPyV TAg-specific polyclonal autologous CD8-positive T cell vaccine;   Biological: aldesleukin;   Other: laboratory biomarker analysis
16 Recruiting Interleukin-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Treating Patients With Merkel Cell Cancer
Conditions: Recurrent Neuroendocrine Carcinoma of the Skin;   Stage I Neuroendocrine Carcinoma of the Skin;   Stage II Neuroendocrine Carcinoma of the Skin;   Stage III Neuroendocrine Carcinoma of the Skin;   Stage IV Neuroendocrine Carcinoma of the Skin
Interventions: Biological: interleukin-12 gene;   Biological: electroporation-mediated plasmid DNA vaccine therapy;   Other: laboratory biomarker analysis
17 Completed S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer
Condition: Neuroendocrine Carcinoma of the Skin
Interventions: Drug: CMF regimen;   Drug: cyclophosphamide;   Drug: fluorouracil;   Drug: methotrexate
18 Completed S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
Conditions: Recurrent Neuroendocrine Carcinoma of the Skin;   Stage II Neuroendocrine Carcinoma of the Skin;   Stage III Neuroendocrine Carcinoma of the Skin
Interventions: Drug: imatinib mesylate;   Other: laboratory biomarker analysis
19 Completed Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors
Conditions: Carcinoma of Unknown Primary;   Neuroendocrine Carcinoma;   Neuroendocrine Carcinoma of the Skin
Intervention: Drug: irinotecan hydrochloride
20 Unknown  Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors
Conditions: Colorectal Cancer;   Gastrointestinal Carcinoid Tumor;   Head and Neck Cancer;   Islet Cell Tumor;   Lung Cancer;   Metastatic Cancer;   Neuroendocrine Carcinoma of the Skin;   Ovarian Cancer;   Pheochromocytoma;   Sarcoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: midazolam hydrochloride;   Drug: nelfinavir mesylate;   Genetic: gene expression analysis;   Genetic: polymerase chain reaction;   Genetic: protein expression analysis;   Other: immunoenzyme technique;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Other: mass spectrometry

Previous Page Studies Shown (1-20) Next Page (21-26) Show next page of results
Indicates status has not been verified in more than two years